Clinical Pearls on Recent Advances and the Future of Treatment in RCC
Mehmet Asim Bilen, MD, summarizes recent advances in metastatic RCC and looks towards the future of the field.
Reflections on Novel Targets and Emerging Regimens for RCC
Arnab Basu, MD, MPH, FACP, weighs in on novel therapeutic targets and emerging regimens that may further improve kidney cancer outcomes.
OncView™ Podcast: Safety and Efficacy of Available Treatment Options and Considerations for Patient Management in Metastatic RCC
In an OncView™ program, David H. Aggen, MD, PhD, Robert S. Alter, MD, Arnab Basu, MD, MPH, FACP, Mehmet Asim Bilen, MD, and Chung-Han Lee, MD, MPH, offer their expert insights for the treatment of RCC.
The Importance of Team-Based Management and Patient Communication
Robert Alter, MD, comments on the importance of team-based care and frequent, timely communication in managing patients with RCC.
Clinical Pearls on Tailoring Dosing Strategies in Metastatic Kidney Cancer
David Aggen, MD, PhD, identifies dosing strategies that may maximize treatment efficacy while minimizing toxicity in patients with kidney cancer.
Considerations for Patient-Focused, Shared Decision-Making in RCC
Chung-Han Lee, MD, PhD, delves into clinical and logistical factors that influence patient-focused, shared-decision making for those with metastatic RCC.
Patient-Specific Factors Impacting Treatment Choices in RCC
Mehmet Asim Bilen, MD, reviews patient-specific factors such as comorbidities, RCC histology, and metastatic status that may factor into treatment decision-making.
Strategies for Prevention and Management of Adverse Events
Chung-Han Lee, MD, PhD, provides a commentary on strategies for preventing and managing treatment-related adverse events in metastatic RCC.
Balancing Treatment Efficacy with Toxicity in Metastatic RCC
David Aggen, MD, PhD, describes the challenges of balancing treatment efficacy versus toxicity and tolerability in patients with kidney cancer.
Common Adverse Events with Single-Agent or Combination Therapy
Mehmet Asim Bilen, MD, provides an overview of commonly observed adverse events in patients with metastatic RCC receiving single-agent or combination therapy.
Safety and Efficacy Data: The CLEAR Trial
David Aggen, MD, PhD, reviews data from the CLEAR trial, which assessed the safety and efficacy of lenvatinib/pembrolizumab versus sunitinib.
Safety and Efficacy Data: The CheckMate 9ER Trial
Robert Alter, MD, reviews the CheckMate 9ER trial of cabozantinib/nivolumab versus sunitinib in advanced renal cell cancer.
Safety and Efficacy Data: The KEYNOTE-426 Trial
Arnab Basu, MD, MPH, FACP discusses data from the KEYNOTE-426 trial of axitinib/pembrolizumab versus sunitinib in metastatic RCC.
Renal Cell Carcinoma: Future Directions in Care
Closing out their discussion on renal cell carcinoma management, experts highlight unmet needs and look toward the future treatment landscape.
Treatment Strategies for Patients Who Progress on Adjuvant Pembrolizumab
Following the advent of adjuvant pembrolizumab in high-risk renal cell carcinoma, experts consider treatment strategies for patients who progress on adjuvant pembrolizumab.
Is Adjuvant Pembrolizumab Standard of Care in Patients at Risk of Recurrence?
Considerations for whether adjuvant pembrolizumab is the new standard of care for patients with renal cell carcinoma at intermediate or high risk of recurrence.
Patient Profile 3: RCC Treated With Adjuvant Pembrolizumab Postnephrectomy
Expert panelists review a clinical scenario of renal cell carcinoma managed with adjuvant pembrolizumab postnephrectomy based on results of the KEYNOTE-564 trial.
Safety and Efficacy Data: The JAVELIN Renal 101 Trial
Chung-Han Lee, MD, PhD, discusses data from the JAVELIN Renal 101 trial of axitinib/avelumab versus sunitinib in metastatic RCC.
Safety and Efficacy Data: The CheckMate 214 Trial
Mehmet Asim Bilen, MD, summarizes data from the CheckMate 214 trial on the safety and efficacy of ipilimumab/nivolumab versus sunitinib.
Patients Suitable for First-Line, Single-Agent Therapy and NCCN-Recommended Regimens
David Aggen, MD, PhD identifies patient populations who may benefit from single-agent therapy and reviews NCCN recommendations for first-line treatment of metastatic clear cell RCC.
Evolution of Combination Therapy As The Standard of Care
Robert Alter, MD, weighs in on the evolution of combination therapy as the first-line standard of care for patients with metastatic clear cell RCC.
Newer First-Line Combination Therapy Options
David Aggen, MD, PhD touches on the availability of newer first-line combination treatment options for metastatic disease.
Comparison of Older First-Line, Single-Agent Therapies
Robert Alter, MD compares older, single-agent first line therapies for patients with metastatic clear cell RCC.
Novel Combination Strategies in the Treatment of Renal Cell Carcinoma
Before closing out their discussion on intermediate-risk RCC, experts review frontline triplet combinations and possible treatment options following relapse after nivolumab-ipilimumab.
Optimizing RCC Management: Addressing Quality-of-Life Measures and Metastasis
Comprehensive discussion on how to best treat patients with renal cell carcinoma and brain or bone metastasis.
Discontinuing IO/IO Therapy in Intermediate-Risk Renal Cell Carcinoma
Shared insight on the adverse event profile of immunotherapy combination regimens in renal cell carcinoma, including advice on when it is appropriate to discontinue therapy.
Patient Profile 2: Intermediate-Risk RCC Treated With Ipilimumab + Nivolumab
Expert perspectives on the clinical scenario of a patient with intermediate-risk renal cell carcinoma, who is managed with the immunotherapy combination of ipilimumab and nivolumab.
Second-Line Therapy Following a TKI/IO Regimen for Favorable-Risk RCC
A brief discussion on available treatment options after patients progress following frontline TKI/IO therapy with favorable-risk renal cell carcinoma.
Favorable-Risk RCC: AE Management and Dosing With TKI/IO Therapy
A comprehensive review of the adverse event profiles of TKI/IO regimens used in favorable-risk renal cell carcinoma and how these can be managed with dose adjustment.
Prognostic Value of Biomarkers in RCC
Robert Alter, MD opines on the current prognostic value of biomarkers for RCC and the need for additional data in the field.
2 Clarke Drive Cranbury, NJ 08512